Antihypertensive Drug | All patients (n = 205) (%) | Patients with target BP <140/90 mmHg (n = 156) (%) | Patients with target BP <130/80 mmHg (n = 49) (%) | PValue* |
---|---|---|---|---|
Loop diuretics | 13.2 | 11.5 | 18.4 | 0.218 |
Furosemide | 13.2 | 11.5 | 18.4 | |
Thiazide diuretics | 66.8 | 64.1 | 75.5 | 0.139 |
Altizide | 1.0 | 0.6 | 2.0 | |
Hydrochlorothiazide | 50.7 | 46.8 | 63.3 | |
Indapamide | 15.1 | 16.7 | 10.2 | |
Potassium-sparing diuretics | 3.9 | 1.3 | 12.3 | 0.003 |
Spironolactone | 2.9 | 1.3 | 8.2 | |
Triamterene | 1.0 | 0.0 | 4.1 | |
Renin inhibitor | 2.0 | 1.9 | 2.0 | 1 |
Aliskiren | 2.0 | 1.9 | 2.0 | |
Angiotensin-converting enzyme inhibitors | 29.8 | 27.5 | 36.8 | 0.221 |
Cilazapril | 1.0 | 1.3 | 0.0 | |
Enalapril | 11.7 | 7.7 | 24.5 | |
Imidapril | 0.5 | 0.6 | 0.0 | |
Lisinopril | 3.4 | 3.2 | 4.1 | |
Perindopril | 6.8 | 9.0 | 0.0 | |
Ramipril | 5.9 | 5.1 | 8.2 | |
Trandolapril | 0.5 | 0.6 | 0.0 | |
Angiotensin II-receptor antagonists | 60.1 | 58.4 | 65.3 | 0.383 |
Candesartan | 6.3 | 7.7 | 2.0 | |
Eprosartan | 2.0 | 1.3 | 4.1 | |
Irbesartan | 8.8 | 8.3 | 10.2 | |
Losartan | 12.2 | 13.5 | 8.2 | |
Olmesartan | 2.0 | 2.6 | 0.0 | |
Telmisartan | 15.1 | 13.5 | 20.4 | |
Valsartan | 13.7 | 11.5 | 20.4 | |
Calcium channel blockers | 39.7 | 36.4 | 48.9 | 0.121 |
Amlodipine | 21.5 | 18.6 | 30.6 | |
Felodipine | 2.0 | 1.9 | 2.0 | |
Lercanidipine | 3.9 | 3.8 | 4.1 | |
Nifedipine | 5.4 | 5.1 | 6.1 | |
Nimodipine | 0.5 | 0.6 | 0.0 | |
Nitrendipine | 1.0 | 1.3 | 0.0 | |
Diltiazem | 5.4 | 5.1 | 6.1 | |
Beta-blockers | 42.6 | 41.6 | 45.0 | 0.689 |
Atenolol | 5.9 | 6.4 | 4.1 | |
Bisoprolol | 5.9 | 6.4 | 4.1 | |
Metoprolol | 0.5 | 0.6 | 0.0 | |
Nebivolol | 23.9 | 21.2 | 32.7 | |
Propranolol | 0.5 | 0.6 | 0.0 | |
Carvedilol | 5.9 | 6.4 | 4.1 | |
Central alpha-2 agonists | 10.8 | 10.8 | 10.2 | 0.888 |
Clonidine | 0.5 | 0.6 | 0.0 | |
Methyldopa | 0.5 | 0.6 | 0.0 | |
Rilmenidine | 9.8 | 9.6 | 10.2 |